Related Experiment Video
Updated: Oct 13, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
CMTM6, a potential immunotherapy target
Jie Liang1, Shaohua Li1, Wei Li1
1Department of Immunology, Medical College of Qingdao University, No. 308 Ningxia Road, Qingdao, Shandong, 266071, People's Republic of China.
Abstract:
The CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6), which binds to the programmed death ligand 1 (PD-L1) and stabilizes the expression of PD-L1 on the cell surface, has been recently discovered as a novel regulator of PD-L1 expression in cancer. PD-L1 is an immune checkpoint inhibitory molecule that can mediate the immune escape of tumor cells in various tumors and has been studied intensively in recent years. In 2017, two articles simultaneously reported that CMTM6 can stabilize the expression of PD-L1 on the plasma membrane and prevent PD-L1 from being degraded by lysosomes; therefore, CMTM6 may play an important role in tumor cell immune escape and immunosuppression. At present, there are few studies on the relationship between the expression of CMTM6 and PD-L1 in different tumors and diseases. These studies together suggested that CMTM6 may be a potential novel immunotherapy target. In this review, we briefly describe the latest research progresses of CMTM6 in various cancers and other diseases.
Insights
The CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6) stabilizes programmed death ligand 1 (PD-L1) expression, impacting tumor immune escape. This review highlights CMTM6 as a potential immunotherapy target in various cancers.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Programmed death ligand 1 (PD-L1) is a key immune checkpoint molecule mediating tumor immune escape.
- Tumor cells utilize PD-L1 to evade the host immune system.
- Understanding PD-L1 regulation is crucial for developing effective cancer immunotherapies.
Purpose of the Study:
- To review the recent research progress on CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6) in various cancers.
- To explore the role of CMTM6 as a novel regulator of PD-L1 expression.
- To evaluate CMTM6 as a potential immunotherapy target.
Main Methods:
- Literature review of studies investigating CMTM6 and PD-L1 expression.
- Analysis of the molecular mechanisms by which CMTM6 affects PD-L1 stability.
- Synthesis of findings from various cancer types and diseases.
Main Results:
- CMTM6 binds to PD-L1 and stabilizes its expression on the cell surface.
- CMTM6 prevents lysosomal degradation of PD-L1.
- Elevated CMTM6 expression is linked to tumor immune escape and immunosuppression.
Conclusions:
- CMTM6 is a critical regulator of PD-L1 expression and plays a significant role in tumor immune evasion.
- CMTM6 represents a promising novel therapeutic target for cancer immunotherapy.
- Further research is warranted to elucidate the full potential of targeting CMTM6 in diverse malignancies.
